The pharma firm reported a US$1.65 billion loss in Q4 2025, driven by a major write-down and falling Covid-19 product sales.

"Providing clarity around modern statistical methods will help sponsors bring more cures and meaningful treatments to ...

PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to ...

Viral vectors and vaccines navigate public distrust while advancing through AI design, COVID response lessons, and promising ...

After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.

Pfizer (PFE) stock dips as the company projects a revenue decline for 2026 amid a nearly $1.5B impact attributed to patent ...

LIBERTY is a Phase 3, randomized, double-blind study to evaluate the safety, serum virus neutralizing antibody responses, and pharmacokinetics of VYD2311, an mRNA COVID vaccine, and co-administered ...

Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues. "Current financial guidance does not anticipate any ...

Pfizer (NYSE: PFE) posted fourth-quarter 2025 revenue of about $18 billion, down 1% from the year-ago quarter, and adjusted ...

New Jersey health insurers have long been required to cover vaccinations, but only if they are recommended by federal ...

Sweeping U.S. policy changes under Health Secretary Robert F. Kennedy Jr. are having a ‌chilling effect ​on vaccine makers as ...